Jakafi 15 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FCRU9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $25,166
Award facts
- Contract value 100% obligated
- $25,165.90 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $25,165.90 to DMS Pharmaceutical Group Inc. for 60 tablets of Jakafi 15 mg, a pharmaceutical product used in the treatment of myelofibrosis and polycythemia vera. The delivery order, awarded on January 14, 2026, with an ultimate completion date of January 15, 2026, carries a firm fixed-price structure and does not utilize a set-aside designation. Performance will take place at the contractor's headquarters in Park Ridge, Illinois. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was selected as the awardee based on its established capability to supply pharmaceutical products to Department of Defense medical facilities.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) designated SPE2DR with the Defense Logistics Agency, awarded in November 2025 under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The underlying IDC carries a $499.999 billion ceiling value and extends through December 31, 2036, positioning the contractor as a critical regional pharmaceutical supplier for DoD healthcare operations. The PPV-G GEN V program represents a $30.3 billion acquisition strategy designed to consolidate pharmaceutical supply chain management across Department of Defense military healthcare facilities worldwide, enabling efficient sourcing of branded and generic prescription medications, biologics, vaccines, and medical consumables through multiple prime vendor contractors.
Quick answers
Who was awarded contract SPE2DR26FCRU9?
SPE2DR26FCRU9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 14, 2026.
How much is contract SPE2DR26FCRU9 worth?
The government has obligated $25,166 on SPE2DR26FCRU9.
Is contract SPE2DR26FCRU9 an order under another contract?
Yes. SPE2DR26FCRU9 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRU9 competed?
The extent of competition for SPE2DR26FCRU9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award